Page 52 - Dermatology Classifier Know What It Doesn T News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dermatology classifier know what it doesn t. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dermatology Classifier Know What It Doesn T Today - Breaking & Trending Today

HCPLive - Clinical news for connected physicians

HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more. ....

Tim Smith , Connor Iapoce , Giuliana Grossi , Morgan Petronelli , Drug Administration Advisory Committee , Pharmaceuticals Inc , Becky Jordan , Internal Medicine , Primary Care , Rare Disease , Infectious Disease ,

Delay of surgical treatment for melanoma up to 90 days not associated with poorer outcomes

1. In this retrospective cohort study, cutaneous melanomas with a classification of T1b-T4 but without clinical evidence of metastatic disease (N0M0) at time of diagnosis, delay of surgical intervention up to 90 days after diagnosis did not increase risk of upstaging disease. Evidence Rating Level: 2 (Good) The current standard of care treatment for cutaneous melanomas ....

United States , University Of Colorado School Medicine , Rating Level , Colorado School ,

HCPLive - Clinical news for connected physicians

HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more. ....

Giuliana Grossi , Kenny Walter , New Drug Application , Internal Medicine , Primary Care , Rare Disease , Infectious Disease ,

HCPLive - Clinical news for connected physicians

HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more. ....

Kenny Walter , Internal Medicine , Primary Care , Rare Disease , Infectious Disease ,

Phase 2 Randomized Trial Supports Roflumilast as a Potential Treatment for Seborrheic Dermatitis

1. Erythema, scaling, and itching caused by seborrheic dermatitis (SD) significantly decreased with roflumilast treatment. 2. Roflumilast treated for SD resulted in favourable local tolerability and safety profile. Evidence Rating Level: 1 (Excellent) Study Rundown: Seborrheic dermatitis (SD) is a chronic dermatosis characterized by erythematous, scaly, and pruritic patches and plaques in areas of high ....

Rating Level , Investigator Global Assessment , Worst Itch Numeric Rating Scale , Seborrheic Dermatitis ,